在HFpEF中寻找有效的治疗方法:对动物疾病建模的影响
Magdalena Jasińska-Stroschein1
1Department of Biopharmacy, Medical University of Lodz, 90-419 Lodz, Poland.
Pharmaceuticals (Basel, Switzerland)
|October 28, 2023
概括
为了有效治疗,开发精确的心力衰竭与保存喷射分数 (HFpEF) 的动物模型至关重要. 目前的模型在改善透缩功能方面显示出希望,但需要加强更广泛的治疗测试.
科学领域:
- 心脏病学 心脏病学
- 翻译医学是一种翻译医学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 随着心力衰竭与保留射出分数 (HFpEF) 的患病率在上升,但缺乏有效的治疗方法.
- 一个重要的障碍是缺乏完全捕捉HFpEF复杂性的动物模型.
- 本综述研究了治疗剂在临床前模型中对HFpEF的影响.
研究的目的:
- 审查HFpEF现有的治疗干预措施.
- 在临床前HFpEF模型中评估各种药物的疗效.
- 为了确定当前HFpEF动物模型中的局限性.
主要方法:
- 从两个数据库中对194个实验协议进行系统审查.
- 分析遵循了PRISMA报告准则.
- 专注于在HFpEF模型中评估治疗剂的研究.
主要成果:
- 评估了150多种物质,包括RNAI,ARB和SGLT-2抑制剂.
- 大多数模型都使用压力过载和高血压,主要评估LV透气功能.
- 腹筋性能有所改善,但肺堵塞和死亡率的研究较少.
结论:
- 目前的临床前模型显示有希望,但需要改进.
- 综合的HFpEF模型需要多器官表型和生理应激测试.
- 改进的模型对于成功转化为临床试验至关重要.
相关概念视频
Heart Failure V: Medical Management
9
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
9
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
438
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
438
Heart Failure II: Pathophysiology
14
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
14
Pathophysiology of Heart Failure
1.6K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.6K
Heart Failure VI: Adjunct Therapies
15
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
15
Heart Failure IV: Classification and Diagnostic Evaluation
18
Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
18


